AbbVie Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?

📈 ABBV stock has risen 8.9% year-to-date and 31.5% over the past year, outperforming the broader industry trend.

💊 Skyrizi and Rinvoq are expected to generate combined sales exceeding $31 billion in 2026 with growth rates above 20%.

🔬 The Parkinson's disease franchise, including Vyalev, holds a peak sales potential of more than $5 billion.

💰 AbbVie recently announced the acquisition of Apogee Therapeutics for approximately $10.9 billion to strengthen its immunology pipeline.

⚠️ Humira sales declined around 50% in 2025 due to biosimilar erosion and plan exclusions.

📉 Analyst earnings estimates for 2026 have dropped from $14.30 to $14.23 over the past 30 days.

🏥 The oncology segment faces offsetting pressures as new drug contributions are being countered by expected declines in Imbruvica sales.

📊 ABBV trades at a forward P/E of 16.07, which is below the industry average of 18.59 but above its five-year mean of 13.99.

📉 The stock carries a Zacks Rank #4 (Sell) rating due to declining estimates and acquisition costs.

🚀 AbbVie expects total revenues to rise around 10% in 2026, driven primarily by immunology and neuroscience products.

Bullish Signals
  • AbbVie has successfully navigated the Humira patent cliff, replacing lost revenue with strong growth from Skyrizi and Rinvoq.
  • Combined Skyrizi and Rinvoq sales are projected to exceed $31 billion in 2026, representing over 20% growth.
  • The Parkinson's disease franchise has a peak sales potential of more than $5 billion, with Vyalev expected to achieve blockbuster status in 2026.
  • AbbVie is executing an acquisition spree, including the $10.9 billion purchase of Apogee Therapeutics, to bolster its late-stage pipeline.
  • The company expects total revenues to rise around 10% in 2026 and high single-digit growth through 2029.
  • ABBV trades at a forward P/E of 16.07, which is lower than the industry average of 18.59, suggesting reasonable valuation.
Risk Factors
  • Humira sales declined around 50% in 2025 due to biosimilar erosion and increasing plan exclusions.
  • The aesthetics segment has seen soft sales for several years, with global projections flat at $5 billion in 2026 due to Juvederm declines.
  • Analyst earnings estimates for 2026 have declined from $14.30 to $14.23 over the past 30 days.
  • Oncology sales have slightly slowed as contributions from new drugs are being offset by expected declines in Imbruvica sales.
  • The stock is trading above its five-year mean P/E of 13.99, indicating it may be relatively expensive compared to historical levels.
  • AbbVie faces competitive pressure from Johnson & Johnson's new oral psoriasis drug Icotyde, which could impact Skyrizi prescription trends.
Full Analysis
AbbVie (ABBV) shares have risen 8.9% year-to-date as investors gain confidence in the company's post-Humira growth strategy. Despite the loss of exclusivity for its blockbuster drug Humira, which saw sales decline around 50% in 2025 due to biosimilar erosion, AbbVie has successfully offset this revenue with strong performance from its immunology portfolio, specifically Skyrizi and Rinvoq. The company expects combined sales of Skyrizi and Rinvoq to exceed $31 billion in 2026, reflecting over 20% growth driven by new indications and market share gains. While the company anticipates low single-digit pricing headwinds and faces competition from Johnson & Johnson's new oral psoriasis drug Icotyde, AbbVie remains confident in navigating these challenges to support top-line expansion. Beyond immunology, AbbVie is leveraging momentum in its neuroscience and oncology segments. The Parkinson's disease franchise, led by Vyalev, has a peak sales potential of over $5 billion, while the oncology pipeline remains robust despite slight slowing in Imbruvica sales. Strategic acquisitions, such as the $10.9 billion deal for Apogee Therapeutics, are further bolstering the late-stage pipeline. From a valuation perspective, ABBV trades at a forward P/E of 16.07, which is lower than the industry average of 18.59 but above its five-year mean. Recent analyst estimates for 2026 and 2027 have declined slightly due to acquisition-related costs. While long-term investors may retain the stock given intact prospects, short-term investors might consider exiting as Zacks Rank #4 (Sell) ratings reflect these near-term estimate pressures.